GSK has informed us they have lifted the allocation restriction for BENLYSTA 400 mg lyophilized powder in single-dose vial (NDC 49401-102-01). Customers may now order based on patient need.
As a reminder, BENLYSTA is also available in 120 mg lyophilized powder in single-dose vial (NDC 49401-0101-01) and in subcutaneous formulation.
GSK regrets any inconvenience the allocation may have caused you and your patients and values the trust that you have in GSK and their medicines.
